Sign up USA
Proactive Investors - Run By Investors For Investors

Namaste Technologies inks deal with BlueSky Biologicals to distribute CBD products in the UK and Europe

Namaste will distribute BlueSky’s range of products, which includes dietary supplements and a pet care line
CBD oil and cannabis leaves
Namaste’s subsidiary Cannmart offers cannabis products through its e-commerce platform

Namaste Technologies Inc (CVE:N, OTCQB:NXTTF) inked a deal with BlueSky Biologicals Inc to distribute its hemp-derived cannabidiol products in the United Kingdom and Europe.

Its subsidiary Namaste Bahamas will distribute BlueSky’s range of products, which includes dietary supplements, personal care, food and beverages and a pet care line.

READ: Namaste Technologies pushes ahead with plan to up-list to Nasdaq

Namaste brings its subsidiaries’ products to the online medical and recreational markets through its subsidiary Cannmart, an e-commerce cannabis platform.

“We have a well-established market in the UK and with recent changes in federal regulations we are now able to launch CBD sales into one of our strongest markets,” said Namaste CEO Sean Dollinger in the company’s press release.

The Vancouver-based company recently signed a wholesale supply agreement with Kief Cannabis Company Ltd, a producer of small-batch, artisan-crafted cannabis.

It has also signed a deal to buy bulk medical cannabis products from Tilray Inc (NASDAQ:TLRY).

Namaste has plans to uplist to the Nasdaq in the hopes of reaching a larger audience of retail and institutional investors.

Shares of Namaste were up more than 2% to US$2.79 in Wednesday afternoon trading.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use